home / stock / cmps / cmps news


CMPS News and Press, COMPASS Pathways Plc From 10/06/23

Stock Information

Company Name: COMPASS Pathways Plc
Stock Symbol: CMPS
Market: NASDAQ
Website: compasspathways.com

Menu

CMPS CMPS Quote CMPS Short CMPS News CMPS Articles CMPS Message Board
Get CMPS Alerts

News, Short Squeeze, Breakout and More Instantly...

CMPS - COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care

(NewsDirect) By Faith Ashmore, Benzinga The Current Landscape Of Mental Health Is Failing Patients Mental health treatments often fail many patients, leaving them struggling to find relief and support. Patients in this category are often considered “treatment-resistant,”...

CMPS - Scientists Concerned Chronic Psychedelic Microdosing Could Result in Valvular Heart Disease

A recent psychedelic study has left researchers concerned that chronic psychedelic microdosing could cause valvular heart disease. Psychedelics have exploded in popularity in recent years thanks to numerous claims of their medical efficacy, leading to an increase in psychedelic microdosing amo...

CMPS - Study Finds Psilocybin Users Less Inclined to Work Overtime

“Quiet quitting” is a phenomenon where employees put in the minimum effort, time and enthusiasm required of them at their jobs and don’t go out of their way to create any extra value for their employers. The trend has picked up a lot of steam in recent years as employees ha...

CMPS - Psychedelic drugs market to break $7B in 2029 led by these 3 meds

2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...

CMPS - Psychedelics research amendments advance in House committee

2023-09-26 13:17:43 ET More on psychedelic drug development Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Qui...

CMPS - Why Element of Play Needs More Attention in Conversations About Psychedelics

After decades of criminalization in most countries across the world, psychedelics are finally having their moment in the light. Early research in the 1950s and 1960s indicated that psychedelics had some therapeutic potential, but new drug-safety policies from the FDA halted further research eff...

CMPS - How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

(NewsDirect) By Faith Ashmore, Benzinga Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatmen...

CMPS - BZUN, CMPS and QSI are among after hour movers

2023-09-20 17:12:25 ET Gainers: Marinus Pharmaceuticals ( NASDAQ: MRNS ) +8% . Complete Solaria ( CSLR ) +5% . Arhaus ( ARHS ) +5% . COMPASS Pathways ( CMPS ) +5% . Quantum-Si  ( QSI ) +5% . Losers: Vahanna Tech ...

CMPS - How Psychedelics Treat Brain Injuries

Psychedelics have exploded in popularity in recent years thanks to a growing body of literature that indicates they may be potent mental-health treatments. Several studies have found that when psychedelics such as LSD, psilocybin and MDMA are paired with traditional talk therapy, they can provide...

CMPS - One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

(NewsDirect) By Faith Ashmore, Benzinga Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond...

Previous 10 Next 10